Journal of Basic Research in Medical Sciences
J Basic Res Med Sci
Volume 12, Issue 3 (5-2025)
jbrms 2025, 12(3): 43-51 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rostami-Mogaddam M, Rezaei L, Mardi A, Sadrinia A. Comparison of the Effect of 2% Finasteride Topical Solution Versus 5% Minoxidil Topical Solution in the Treatment of Androgenic Alopecia in Men: A Quasi-Experimental Study. jbrms 2025; 12 (3) :43-51
URL: http://jbrms.medilam.ac.ir/article-1-913-en.html
URL: http://jbrms.medilam.ac.ir/article-1-913-en.html
Department of Dermatology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran , rostamimajid665@gmail.com
Abstract: (19 Views)
Introduction: About 50% of men experience different types of hair loss by the age of 50. To treat this problem, based on the Food and Drug Administration (FDA), the aim of this study was to compare the effect of 2% topical finasteride solution versus 5% topical minoxidil solution in the treatment of androgenic alopecia in men.
Materials & Methods: The study was quasi-experimental and was conducted on 194 men with the initial complaint of hair loss in the dermatology clinic of Imam Reza Hospital in Ardabil during September 2020 and June 2021, who were randomly divided into two equal groups by the random block method. Data were collected by a checklist and then analyzed by using descriptive statistical methods in SPSS V.21. The significance level was considered less than 0.05.
Results: In the minoxidil and finasteride group, the pull test was negative in 17.7% and 24.5% of patients during the first month, respectively. In 2-3% of patients in the minoxidil group, tension headache and scalp irritation were reported, but no such side effects were found in the finasteride group. In general, reduction of hair loss and hair regrowth during six months of continuous use of the drug was observed in 65.6% of patients in the minoxidil group and 85.4% of patients in the finasteride group.
Conclusion: Topical solutions of finasteride and minoxidil were effective and safe in the treatment of mild to severe androgenetic alopecia in men.
Materials & Methods: The study was quasi-experimental and was conducted on 194 men with the initial complaint of hair loss in the dermatology clinic of Imam Reza Hospital in Ardabil during September 2020 and June 2021, who were randomly divided into two equal groups by the random block method. Data were collected by a checklist and then analyzed by using descriptive statistical methods in SPSS V.21. The significance level was considered less than 0.05.
Results: In the minoxidil and finasteride group, the pull test was negative in 17.7% and 24.5% of patients during the first month, respectively. In 2-3% of patients in the minoxidil group, tension headache and scalp irritation were reported, but no such side effects were found in the finasteride group. In general, reduction of hair loss and hair regrowth during six months of continuous use of the drug was observed in 65.6% of patients in the minoxidil group and 85.4% of patients in the finasteride group.
Conclusion: Topical solutions of finasteride and minoxidil were effective and safe in the treatment of mild to severe androgenetic alopecia in men.
Type of Study: Research |
Subject:
Dermatology
Received: 2024/11/20 | Accepted: 2025/02/15 | Published: 2025/05/11
Received: 2024/11/20 | Accepted: 2025/02/15 | Published: 2025/05/11
References
1. Danyal M, Shah S. I. A, Hassan M. S. U, Qureshi W. Impact of androgenetic alopecia on the psychological health of young men. Pakistan Journal of Medical & Health Sciences.2018; 12(1) :406–410.
2. Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol. 2022 May;21(5):1841-1848. doi: 10.1111/jocd.14895. Epub 2022 Mar 14. PMID: 35238144.
3. York K, Meah N, Bhoyrul B, Sinclair R. A review of the treatment of male pattern hair loss. Expert Opin Pharmacother. 2020;21(5):603–612. doi:10.1080/14656566.2020.1721463
4. Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018;17(4):457-463. PMID: 29601622; PMCID: PMC6609098.
5. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021 Dec;20(12):3759-3781. doi: 10.1111/jocd.14537. Epub 2021 Nov 6. PMID: 34741573; PMCID: PMC9298335.
6. Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018;17(4):457-463. PMID: 29601622; PMCID: PMC6609098.
7. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of Finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47-51. doi: 10.4103/0378-6323.45220. PMID: 19172031.8.
8. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel Finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842-9. doi: 10.5414/CP202119. PMID: 25074865.
9. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021 Dec;20(12):3759-3781. doi: 10.1111/jocd.14537. Epub 2021 Nov 6. PMID: 34741573; PMCID: PMC9298335.
10. Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257-2263.
11. Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% Finasteride admixed with 3% Minoxidil vs. 3% Minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257-2263. doi: 10.1111/jdv.15171. Epub 2018 Jul 20. PMID: 29972712.
12. Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical Minoxidil fortified with Finasteride: An account of maintenance of hair density after replacing oral Finasteride. Indian Dermatol Online J. 2015;6(1):17-20. doi: 10.4103/2229-5178.148925. PMID: 25657911; PMCID: PMC4314881.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |